Sanofi's experimental drug lunsekimig successfully met primary and key secondary endpoints in phase 2 trials for moderate-to-severe asthma and chronic rhinosinusitis with nasal polyps, demonstrating significant improvements in lung function and symptom reduction. The drug, designed to block two inflammation drivers, was well tolerated with a favorable safety profile. However, an exploratory study in atopic dermatitis did not meet its primary endpoint, though some secondary improvements were noted. These results support lunsekimig's potential as a novel treatment for respiratory diseases, with further phase 2 and 3 studies ongoing.
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Paulo Fontoura has resigned from the Board of Directors at Lakefront Biotherapeutics following his appointment as Executive Vice President and Global Head of Research & Development Pharma at Sanofi. Lakefront's board chair congratulated Fontoura and ...
